Risk of all-cause death and major adverse cardiovascular events for men and women with type 2 myocardial infarction
| HR (95% CI) | P value | |
| All-cause death* (men, ref cat) | ||
| Model 1 (crude) | 0.82 (0.75 to 0.90) | <0.001 |
| Model 2 (model 1+adjusted for comorbidities) | 0.81 (0.74 to 0.90) | <0.001 |
| Model 3 (model 2+adjusted for hs-cTnT concentrations) | 0.84 (0.76 to 0.92) | ≤0.001 |
| Major adverse cardiovascular events† (men, ref cat) | ||
| Model 1 (crude) | 0.87 (0.80 to 0.95) | 0.002 |
| Model 2 (model 1+adjusted for comorbidities) | 0.92 (0.84 to 1.01) | 0.067 |
| Model 3 (model 2+adjusted for hs-cTnT concentrations) | 0.94 (0.86 to 1.03) | 0.189 |
Model 1: sex, hospital site, year; model 2: model 1+age, current smoking, hypertension, diabetes, hyperlipidaemia, coronary artery disease, congestive heart failure, previous stroke, ST-segment depression, estimated glomerular filtration rate, COPD, dementia, previous or present cancer; model 3: model 2+hs-cTnT levels.
*Patients with type 2 myocardial infarction, n=4119.
†Patients with type 2 myocardial infarction, n=3979.
COPD, chronic obstructive pulmonary disease; hs-cTnT, high-sensitivity cardiac troponin T; ref cat, reference category.